Protocol H8H- MC-LAHT(c)  
Safety, Tolerability, and Pharmacokinetics of Lasmiditan when Co- administered with 
Topi[INVESTIGATOR_157610]  
 
[STUDY_ID_REMOVED] 
Approval Date: 20- Oct-2017 
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 1
LY573144Protocol H8H -MC-LAHT(c)
Safety , Tolerability , and Pharmacokinetics of Lasmiditan 
when Co -administered with Topi[INVESTIGATOR_157611].  It is the property of Eli Lilly and Company or its subsidiaries and 
should not be copi[INVESTIGATOR_72118] (LY573144 ), unless such persons are bound by a confidentiality agreement with 
Eli Lilly and Company or its subsidiaries.
Note to Regulatory Authorities:   This document may contain protected personal data 
and/or commerciall y confidential information exempt from public disclosure.  Eli Lilly and 
Company requests consultation regarding release/redaction prior to any public release.  In 
the [LOCATION_002], this document is subject to Freedom of Information Act (FOIA) 
Exemption 4 and may not be reproduced or otherwise disseminated without the written 
approval of Eli Lilly and Company or its subsidiaries.
Lasmiditan (LY573144)
Eli Lilly and Company
Indianapolis, Indiana [LOCATION_003] [ZIP_CODE]
Clinical Pharmacology Protocol Electronically Sign ed and Approved by [CONTACT_11007]: 
[ADDRESS_182351] 2017
Amendm ent (a) Electronical ly Signed and Approved by [CONTACT_11007]: 05 September 2017
Amendm ent (b) Electronical ly Signed and Approved by [CONTACT_11007]: 11 October 2017
Amendm ent (c) Electronical ly Signed and Approved by [CONTACT_82356].
Approval Date: 20-Oct-2017 GMT
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 2
LY573144Table of Contents
Safety , Tolerability , and Pharmacokinetics of Lasmiditan 
when Co -administered with Topi[INVESTIGATOR_157612] l H8H -MC-LAHT(c) Safet y, Tolerabilit y, and Pharmacokinetics of 
Lasmiditan when Co -administered with Topi[INVESTIGATOR_157613] .............................................................................................................................. [ADDRESS_182352] ivities....................................................................................................... 10
3. Introduction ...................................................................................................................... 16
3.1. Study  Rati onale ............................................................................................................ 16
3.2. Background .................................................................................................................. 16
3.3. Benefit /Risk Assessment .............................................................................................. [ADDRESS_182353] yle and/or Dietary Requirements ......................................................................... 25
6.3.1. Meals and Dietary  Restri ctions............................................................................. 25
6.3.2. Caffeine, Alcoho l, and Tobacco ........................................................................... 25
6.3.3. Activity................................................................................................................ 25
6.4. Screen Failures ............................................................................................................. 25
7. Treat ment .......................................................................................................................... 26
7.1. Treatment Administered ............................................................................................... 26
7.1.1. Packaging and Labeling ....................................................................................... 27
7.2. Method of Treatment Assignment ................................................................................ 27
7.2.1. Selection and Timing o f Doses ............................................................................. 27
7.3. Blinding ....................................................................................................................... 27
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 3
LY5731447.4. Dose Modificat ion........................................................................................................ 27
7.5. Preparati on/Handling/Storage/Accountabilit y............................................................... [ADDRESS_182354] to Follow -up........................................................................................... 30
9. Study  Assessments and Procedures ................................................................................... 31
9.1. Efficacy Assessments ................................................................................................... 31
9.2. Adverse Events ............................................................................................................ 31
9.2.1. Serious Adverse Events ........................................................................................ 32
[IP_ADDRESS]. Suspected Unexpected Serious Adverse React ions.......................................... 32
9.2.2. Com plaint Handling ............................................................................................. 33
9.3. Treatment of Overdose .................................................................................................33
9.3.1. Overdose of Lasmiditan ....................................................................................... 33
9.3.2. Overdose of Topi[INVESTIGATOR_052] ....................................................................................... 33
9.4. Safety........................................................................................................................... 33
9.4.1. Laboratory  Tests .................................................................................................. 33
9.4.2. Vital Signs ........................................................................................................... 33
9.4.3. Electrocardi ogram s.............................................................................................. 34
9.4.4. Columbia Suici de Severi ty Rating Scal e............................................................... 34
9.4.5. Neurol ogical Examinat ions.................................................................................. 35
9.4.6. Safety Moni toring ................................................................................................ 35
[IP_ADDRESS]. Hepati c Safet y................................................................................................ [ADDRESS_182355] ics.......................................................................... 38
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 4
LY57314410.3. Statistical Analyses ...................................................................................................... 38
10.3.1. Safety Analyses .................................................................................................... 38
[IP_ADDRESS]. Clinical Evaluation of Safet y.......................................................................... 38
[IP_ADDRESS]. Statistical Evaluat ion of Safet y....................................................................... 39
10.3.2. Pharmacokinet ic Analyses .................................................................................... 39
[IP_ADDRESS]. Pharmacokinet ic Parameter Estimat ion........................................................... 39
[IP_ADDRESS]. Pharmacokinet ic Statistical Inference ............................................................. 39
11. References ........................................................................................................................ 40
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page [ADDRESS_182356] ives and Endpo ints....................................................................... 18
Table LAHT.2. Treatments Administered ........................................................................ 26
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page [ADDRESS_182357] of Figures
Figure Page
Figure LAHT.1. Illustrati onof study  design for Protocol H8H -MC-LAHT. ...................... 20
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page [ADDRESS_182358] of Appendices
Appendix Page
Appendix 1. Abbreviat ions and Definit ions................................................................ 41
Appendix 2. Clinical Laboratory  Tests ........................................................................ 45
Appendix 3. Study  Governance, Regulatory , and Ethi cal Considerati ons.................... 46
Appendix 4. Hepati c Moni toring Tests for Treatment -Emergent Abnormalit y............ 49
Appendix 5. Blood Sam pling Summary ...................................................................... 50
Appendix 6. Neurol ogical Examinat ions..................................................................... 51
Appendix 7. Protocol  Amendment H8H -MC-LAHT(c)  Summary  Safety, 
Tolerabilit y, and P harm acokinetics of Lasmiditan when Co -
administered with Topi[INVESTIGATOR_157614] .................................53
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 8
LY5731441.Protocol Synopsis
Title of Study:
Safety, Tolerability, and Pharma cokinetics of Lasmiditan when Co -administered with Topi[INVESTIGATOR_157615]: 
Topi[INVESTIGATOR_157616].  Study H8H-MC -LAHT ( LAHT )is being conducted to evaluate the safety ,tolerability ,and 
pharmacokinetics ( PK)of lasmiditan when co -administered with topi[INVESTIGATOR_157617].
Objective(s)/Endpoints:
Objectives Endpoints
Primary
Toevaluate the safety and tol erability  of 
a single dose of l asmiditan in 
combinatio n with topi[INVESTIGATOR_157618].A summary of the number of treatment -emergent 
adverse events and serious adverse events .
Secondary
To evaluate the PK of lasmiditan alone 
andin combination with topi[INVESTIGATOR_157619].
To evaluate the PK of topi[INVESTIGATOR_157620] .Maximum observed drug concentration (Cmax), time of 
Cmax(tmax), area under the concentration versus time 
curve from zero to last, and zero to infinity
Cmax, tmax, and area under the concentration versus time 
curve during 1dosing interval
Summary of Study Design :  
Study LAHT i s a parallel , placebo -controlled, fixed -sequence study that assesses the safety, tolerability, and 
potential for PK interaction between investigator -and subject -blind lasmiditan /placebo and open -label topi[INVESTIGATOR_052].
A single dose of lasmiditan (200 mg) or placebo will be administered on the morning of Day 1. Topi[INVESTIGATOR_052] 25 mg 
once daily (Day 3), 25 mg twice daily ( BID)(Day s 4to 7),50mg BID (Day s 8to 13), followed by a single 50-mg 
dose on the morning of Day 14will be administered . A single dose of lasmiditan (200 mg) or placebo will be 
co-administered with topi[INVESTIGATOR_052] (50mg)on the morning of Day 14.
Treatment Arms and Planned Duration for Subjects :
  
Screening Period: All subjects will participate in a screening visit of up to 28 days.  
Treatment period: The subjects will be admitted to the clinical research unit (CRU) on the day before dosing 
(Day  -1).  Subjects will be discharged from CRU on Day [ADDRESS_182359] been completed.
Follow -up period: Subjects will be discharged from the stud y approximately  [ADDRESS_182360] dose of 
topi[INVESTIGATOR_052].
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 9
LY573144Number of subjects :
Approximately 30subjects may be enrolled so that at least 21complete the study.
Statistical Analysis:
Safety parameters that will be assessed include safety laborator y param eters, vital signs, neuro logical exam ination , 
Columbia Suicide Severity Rating Scale , and 12-lead electrocardiogram parameters.  The parameters will be listed, 
and summarized using standard descriptive statistics , as appropriate .  
Pharmacokinetic paramete r estimates for lasmiditan ,its metabolites ,and topi[INVESTIGATOR_157621].   
The parameters will be listed, and summarized using standard 
descriptive statistics , as appropriate .
Pharmacokinetic parameters will be evaluated to determine the impact of topi[INVESTIGATOR_157622] -administration on the PK of 
a single dose of lasmiditan and its metabolites .  Log -transformed C maxand area under the concentration versus time 
curve parameters will be evaluated in a li near mixed-effects model with fixed effects for treatment (lasmiditan co -
administered with topi[INVESTIGATOR_052] [Day 14; test treatment] versus lasmiditan alone [Day 1; reference treatment]), and a 
random effect for subject.  The treatment differences will be back -transformed to present the ratios of geometric 
means and the corresponding 90% confidence interval (CI).
A similar analysis will be performed to determine the impact of co -administratio n of a single dose of lasmiditan on 
the steady -state PK of topi[INVESTIGATOR_052].  The model will include the following treatments:  topi[INVESTIGATOR_157622] -administered 
with lasmiditan (Day 14; test treatment) versus topi[INVESTIGATOR_157623] (Day 13; reference treatment).
The t maxwill be analyzed using the Wilcoxon signed rank test.  Estimates of the median difference based on the 
observed medians, 90% CIs, and p -values from the Wilcoxon test will be calculated.
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 10
LY5731442.Schedule of A ctivities
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 11
LY573144Study Schedule Protocol H8H -MC-LAHT
Screening Study Days Discharg
eFollow -
up/EDComments
Procedure -28 to -2 
days 
prior to 
Day 1-1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Day 16 ~[ADDRESS_182361] Discharge 
from CRUX
Lasmiditan/Placebo 
AdministrationX
Day 1, 
indicates 
Time = 
0X
Topi[INVESTIGATOR_157624]
X X X X X X X X X X X X25 mg QD on 
Day 3, 25 mg 
BID from Day 4 
to 7, 50 mg BID 
from Day 8 to 
13, a single 50 -
mg dose on the 
morning of Day 
14
Neuro logical
Exam ination
X X X X X X X XOn dosing days, 
alltime points
predose and 4 -
hour postdose
for morning 
dose only.  Day 
3 is predose 
only. Non -
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 12
LY573144Screening Study Days Discharg
eFollow -
up/EDComments
Procedure -28 to -2 
days 
prior to 
Day 1-1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Day 16 ~[ADDRESS_182362] 
dose
dosing days at 
single time 
point. 
C-SSRS /Self -Harm X X X X
Medical History X
Height X
Weight
X X XBody weight 
should be 
recorded on Day 
-1 of all study 
periods.  
Vital Signs 
(supi[INVESTIGATOR_050])
X X0,2, 4, 
8 h24
h0 & 2 h0 
& 
2
h0 
& 
2
h0, 2, 4, 
8 h0, 2, 4, 
8 h24h X XOn dosing days, 
time points 
correspond to 
morning dose 
only.  Day 3 
time points at 
evening dose.
Time points 
may be added 
for each study 
period, if 
warranted and 
agreed upon 
between Lilly 
and the 
investigator.
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 13
LY573144Screening Study Days Discharg
eFollow -
up/EDComments
Procedure -28 to -2 
days 
prior to 
Day 1-1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Day 16 ~[ADDRESS_182363] 
dose
Triplicate BP 
monitoring
Orthostatic Blood 
Pressure
X0, 2, & 4 
h0, 2, & 
4 h0, 2, & 
[ADDRESS_182364] 
will be 
performed at 
every admission 
period and at 
poststudy, if 
applicable.
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 14
LY573144Screening Study Days Discharg
eFollow -
up/EDComments
Procedure -28 to -2 
days 
prior to 
Day 1-1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Day 16 ~[ADDRESS_182365] 
dose
Physical 
Exam inationX X Predose X After screening, 
medical 
assessment is 
performed  only 
to include 
medical review 
and targeted 
examination, as 
appropriate.
12-L ead ECG X Predose X X X X X X Single ; all at 
predose for 
morning dose 
only.
AE/Medication 
ReviewX X X X X X X X X X X X X X X X X X
Lasmiditan and 
Metabolite PK 
SamplesPredose, 
0.5, 1, 
1.5, 2, 3, 
4, 6, 8, 
12h24, 
36
h48hPredose, 
0.5, 1, 
1.5, 2, 
2.5, 3, 
4, 6, 8, 
12h24, 
36h48h
Topi[INVESTIGATOR_157625], 
0.5, 1, 
1.5, 2, 
3, 4, 6, 
8, 12 hPredose, 
0.5, 1, 
1.5, 2, 
3, 4, 6, 
8, 12 hTime points at 
morning dose 
only.
Genetic Sample X
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 15
LY573144Abbreviations: BID = twice daily; BP= blood pressure; CRU = clinical research unit; C-SSRS = Columbia Suicide Severity Rating Scale ;ECG = electrocardiogram ; ED = early discontinuation ; h = 
hour; min = minutes; PK = pharmacokinetics ; QD = once daily . 
Note:  if multiple procedures take place at the same time point, the following order of the procedure should be use d: ECG, vital signs, and venipuncture.
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 16
LY5731443.Introduction
3.1. Study Rationale
Lasmiditan is a small mo lecule serotonin (5 -hydroxytryptamine 1F)receptor agonist being 
developed for the acute treatment of migraine.
Topi [INVESTIGATOR_157626]. As such, it is important to understand 
potenti al interact ions between drugs commo nly used in treating migraine, specifically, whether 
co-administration of such agents results in an increased safet y risk or any change in the exposure 
toeither (or both). Very  comm on adverse events (AEs) (≥1/10) associated with topi[INVESTIGATOR_157627], somno lence, paresthesia, nausea ,and fatigue (Topi [INVESTIGATOR_157628] [https://www.topamax.com/files/topamax. pdf]).  Given the occurren ce of similar 
AEs observed fo llowing administration of single doses of lasmiditan as documented in 
Secti on3.2, it is important to understand the tolerabilit y when both are co -administered.
Topi [INVESTIGATOR_157629] .  
Six metabolites have been ident ified in humans, none of which const itutes m ore than 5% of an 
administered dose.  The metabo lites are form ed via hydroxylat ion, hydro lysis, and 
glucuronidat ion.  In vitro studies indicate that topi[INVESTIGATOR_157630] y for 
cytochrom e P450 (CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, CYP2E1, and CYP3A4/5 
isozymes.  In vitro studies indicate that topi[INVESTIGATOR_24157] a mild inhibitor of CYP2C19 and a mild 
inducer of CYP3A4 (Topi [INVESTIGATOR_157631] 
[https://www.topamax.co m/files/topam ax.pdf]) . 
Following exploratory  analysis of human plasma samples from adult subjects receiving oral 
lasmidit an, 3 m ajor human metabolites (M7, M8, and [S,R]- M18) were observed.  Ketone 
reducti on of  lasmidi tan to M8 (al coho l) appears to be the maj or m etabolic pathway, presumably
vianon-CYP enzymes.  In human liver microsomes, CYP1A2 and CYP3A4 appear to be 
involved to a minor extent in lasmiditan metabo lism.  Unchanged lasmiditan comprises 
approximately  2% of  the dose excreted in urine.  Lasmidita n is a very  weak inhibitor of 
CYP3A4, CYP2D6, and P -glycoprotei n.
Although the probabilit y of a pharmacokinet ic (PK) drug-drug i nteracti on between lasmiditan 
and topi [INVESTIGATOR_157632] l ow inhibitory  potenti al of both drugs and 
their diverse eliminat ion pathways, a study  of their PK interaction is being conducted as a 
secondary  endpoint to the safet y and tol erabili ty of both drugs because of the likelihood for 
concomitant use in clinical pract ice.
3.2. Background
Across the completed Phase 1, 2, and [ADDRESS_182366] frequent ly reported lasmiditan treatment -emergent adverse events (TEAEs) 
included dizziness, paresthesia, somno lence, fatigue, lethargy , and nausea . The majo rity of these 
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page [ADDRESS_182367] wi thdrawal .  One patient 
experienced a serious adverse event (SAE) of dizziness that was moderate in severit y (lasmidi tan 
200 m g).
Oral tablet doses of lasmiditan up to 400 mg did not result in any clinically relev ant changes in 
electrocardi ogram s (ECGs) (including QT interval/corrected QT interval [QTc]) following 
administration to healthy  subjects. In the thorough QT study in healthy subjects, no clinically  
significant changes in bl ood pressure, heart rate, or 12 -lead ECG were observed at the 100- or 
400-mg single -dose l evels .  Lasmidi tan caused no si gnificant QT prol ongat ion at ei ther dose.
In healthy subjects, peak plasma concentrations of lasmiditan were observed appr oximately 1 to 
2.5 hours after a single oral dose ranging fro m 25 to 400 m g, and the geometric mean terminal 
half-life was approximately 4 to 6 hours.  Lasmidit an exhibited dose -linear PK; low to moderate 
intersubject variabilit y in exposure was observed a cross doses (%coefficient of variat ionup to 
61% and 45% for maximum observed drug concentration [Cmax] and area under the concentration 
versus time curve [AUC], respectively ).  Co-administration of lasmiditan with a high -fatdiet led 
to a delay in median t ime of maximum observed drug concentration (t max) value by  
[CONTACT_3450]  [ADDRESS_182368] (~20%) increase in lasmiditan C maxand AUC values, relat ive 
to that under fasted condit ions.
3.3. Benefit/Risk Assessment
The primary  object ive o f this study  is to eval uate the safet y and tol erabili ty of a single dose of 
lasmiditan in co mbinat ion with topi[INVESTIGATOR_157633]. There i s no anti cipated 
therapeuti c benefit for the subjects.
No clinically  significant safet y or tol erabilit y conce rns have been identified in subjects to date 
for lasmidi tan up to the highest single oral dose given (400 mg).  Dosing of lasmiditan in this 
study  will be conducted in an inpat ient setting, and subjects will be monitored in the clinical 
research unit (CRU )for at least [ADDRESS_182369] igator’s Brochure (IB).  
Topi [INVESTIGATOR_24157] a marketed drug and will be administe red within a dose titration regimen that has 
been tol erated in previous PK studi es in heal thy subjects ( e.g. Bi aler et al. 2013 ;Mani tpi[INVESTIGATOR_157634]. 2014a,b).
More detailed informat ion about the known and expected benefits and risks of topi[INVESTIGATOR_157635]:  2017 US Prescribing Informat ion.
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page [ADDRESS_182370] ives and endpo ints of the study .
Table LAHT.1. Objectives and Endpoints
Objectives Endpoints
Primary
To evaluate the safety and tolerability of a single dose 
of lasmiditan in combination with topi[INVESTIGATOR_157618]. A summary of the number of treatment -emergent 
adverse events and serious adverse events
Secondary
To evaluate the pharmacokinetics of lasmiditan alone 
and in combination with topi[INVESTIGATOR_157617].
To evaluate the pharmacokinetics of topi[INVESTIGATOR_157620] .Cmax, tmax, AUC([ADDRESS_182371]) and AUC(0 -∞)
Cmax, tmax, and AUC 
Exploratory
To evaluate the pharmacokinetics of lasmiditan 
metabolites alone and in combination with topi[INVESTIGATOR_157636].Cmax, tmax, AUC([ADDRESS_182372]) ,and AUC(0 -∞)
Abbreviations:  AUC([ADDRESS_182373]) = area under the concentration versus time curve from time zero to time t, where t is 
the last time point with a measurable concentration; AUC(0 -∞)= area under the concentration versus time curve
from zero to infinity; AUC= area under the concentration versus time curve during 1 dosing interval; Cmax= 
maximum observed drug concentration ; tmax= time to Cmax.
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page [ADDRESS_182374] -blind administration of 
lasmiditan /placebo conducted in healthy subjects.
Subjects will be admitted to the CRU on Day  -1 and are expected to remain a resident until all 
assessments are completed on Day  16;however ,subjects m ay be allowed to leave the CRU at 
the discret ion of the invest igator. 
Study  governance considerations are described in detail in Appendix 3 .
Lasmiditan and topi[INVESTIGATOR_157637]. Subjects will be rando mly 
assigned in a 2:1 ratio to receive lasmiditan or placebo on both lasmiditan dosing days (Days 1 
and 14).  A single oral dose of study  drug (200-mglasmiditan or placebo) will  be administered in 
the morning on Day  1. After lasmiditan wash -out, t opi[INVESTIGATOR_157638] 100mg on 
Days 3 to 13. On Day 14, 1 oraldose of l asmidi tan 200 m gor placebo will be co -administered
with the final topi[INVESTIGATOR_157639] (50 m g) in the morning.
Blood sam pling for PK assessment will be conducted predose and at time points up to [ADDRESS_182375] 10 days following co -administration of lasmiditan and 
topi[INVESTIGATOR_052] (Day  14).
Figure LAHT .1illustrates the study  design.
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 20
LY573144Abbreviations: LY = lasmiditan (200 mg); n = number of subjects in each group ; P = 
placebo.
Symbols: “25” inside a circle = one 25-mg tablet of topi[INVESTIGATOR_052] ; gray pentagon =
lasmiditan dose or placebo .
Figure LAHT.[ADDRESS_182376] scheduled procedure shown in the Schedule o f 
Activities(Secti on
 2) for the last subject .
5.4. Scientific Rationale for Study Design
Subjects will be rando mly assigned to 1 of 2 treatment arms.  Treatment arms run in parallel and 
both receive the same topi[INVESTIGATOR_157640]. One treatment arm will receive lasmiditan 
(200 m g) on Day s 1 and 14 when the other receives a lasmiditan placeb o to control  for observed 
AEs.
The study  has a doubl e-blind (subject -and invest igator-blind), fixed -sequence design in which 
each subject receives lasmiditan or placebo alone, topi[INVESTIGATOR_157623], and lasmiditan or placebo 
co-administered with topi[INVESTIGATOR_052], allowing each subject to act as his/her own control for safet y 
and PK comparisons. A single [ADDRESS_182377] 

H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 21
LY573144potenti al recommended dose for l asmidi tan.  The washout peri od between l asmidi tan doses of 
14days is considered sufficient based on the half -life of lasmiditan of approximately 4 to 
6hours. Topi[INVESTIGATOR_157641] a titration schedule over a period of 12 days to 
aid tolerabilit y, with a single dose of lasmiditan or placebo co -administered on the final day, to 
ensure that topi[INVESTIGATOR_157642] .
5.5. Justif ication for Dose
The dose level o f 200-mg lasmiditan has been well tolerated in previous studies of healt hy 
subjects; [ADDRESS_182378] recommended single dose of lasmiditan. 
As described in the label, topi[INVESTIGATOR_157643] 25 mg/day (Day  3), increased to 50 mg/day 
(Day s 4to 7),and maintained at 100 mg/day (Days 8 to 13).Therecommended dosage for 
migraine prophylaxis is 100 mg/day (Topi[INVESTIGATOR_157644] 
[https://www.topamax.co m/files/topam ax.pdf])
. Similar topi[INVESTIGATOR_157645] y profiles ( Bialer et al . 2013 ; 
Mani tpi[INVESTIGATOR_157646] . 2014a ) and are generally well tolerated ( Manitpi[INVESTIGATOR_157646]. 2014b).
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page [ADDRESS_182379] ing 
condi tions will  be docum ented.
Screening may occur up to 28 day sprior to enrollment.  Subjects who are not enrolled within 
28daysof screening may  be subjected to an addit ional medical assessment and/or clinical 
measurements to confirm their eligibilit y.
Prospective approval o f protocol  deviati ons to recrui tment and enro llment criteria, also known as 
protocol  waivers or exempt ions, is not permitted.
6.1. Inclusion Criteria
Subjects are eligible for inclusio n in the study  only if they  meet all  of the following criteria at 
screening :
[1] are overtly healt hy males or females, as determined by  [CONTACT_72134].
[1a]male subjects:
are not required to adhere to con tracepti ve requi rements . 
[1b] female subjects:
ofnon-childbeari ng potenti al, i.e.,postmenopausal or permanent ly sterile 
following hysterectomy, bilateral salpi[INVESTIGATOR_1656] ,or confirmed tubal 
occlusion (not tubal  ligation),as determined by [CONTACT_157668] .  Postm enopausal  is defined as spontan eous am enorrhea for at least 
12months, and a plasma fo llicle -stimulating hormone level greater than 
40mIU/mL, unless the subject is taking hormone replacement therapy  
(HRT). 
[2] are a ged18 to 65 years at the time of screening. 
[3] have a body  mass index (BMI) of 19.0 to 35.0 kg/m 2, inclu sive, at the time of 
screening.
[4] h ave clinical laboratory  test resul ts wi thin norm al reference range for the 
popul ation or invest igativesite, or resul ts wi th acceptabl e deviat ions that are 
judged to be not clinically signifi cant by  [CONTACT_093] .
[
5] have venous access sufficient to allow for blood sampling as per the protocol .
[6] are reliable and willing to make themselves available for the duration of the 
study  and are willing to follow study  procedures .
[
7]have given written informed consent approved by  [CONTACT_105331] (ERB) governing the site.
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 23
LY5731446.2. Exclusion Criteria
Subjects will be excluded fro m study  enro llment if they meet any o f the following cri teria at 
screening and/or enrollment:
[8] are CRU personnel directly affiliated with this study and their immediate 
families.  Immediate family is defined as a spouse, bio logical or legal 
guardi an, child, or sibling.
[
9]are Lilly  or Covance empl oyees.
[10]are currently enrolled in a clinical  study  involving an invest igational product 
(IP) or any  other ty pe of medical research judged not to be scient ifically or 
medically co mpat ible with this study.
[11] have known allergies to lasmiditan , topi [INVESTIGATOR_052] , related compounds or any  
components of the formula tion of  lasmidi tan or topi[INVESTIGATOR_052].
[12]are persons who have previously received th e IPin this study , withdrawn fro m 
this study ,or received lasmiditan in any other study  invest igating lasmidi tan.
[13] have participated (dosed with IP [lasmidi tan or pl acebo]), within the past
30days, in a clinical study  involving an IP.  If the previous IPhas a long 
half-life, 5 half -lives or 30 days (whichever i s longer) shoul d have passed.
[
14] have a history  of, or ECG findings of, clinically significant brady cardia, heart 
block, tachy  or brady  arrhy thmias, or have an y other abnormalit y in the 
12-lead ECG that, in the opi[INVESTIGATOR_3078] n of the invest igator, increases the risks 
associ ated wi th parti cipat ingin the study . 
[15] have an abnormal supi[INVESTIGATOR_9204], defined as systolic blood pressure 
<90 or >140 mmHg or diastolic blood pressure <60 or >90 mmHg at 
screening.  Repeat assessment smay be perform ed to confirm eligibilit y.
[
16] ha ve a significant history  of or current card iovascular, respi[INVESTIGATOR_696] (including 
bronchospasm or bronchial asthma, or chronic obstructive airways disease) , 
hepat ic, renal, gastrointest inal, endocrine, hematological, or neurological 
disorders capable o f significant ly altering the absorpti on, m etabolism , or 
eliminat ion of drugs; of constituting a risk when taking the study  medicat ion; 
or of interfering wit h the interpretation of data .  Appendectomy, splenectomy, 
and cho lecystectomy are considered as acceptable.
[
17] show a histo ry of central  nervous sy stem  (CNS) condit ions such as strokes, 
transi ent ischemic attacks, significant head trauma, CNS infect ions, migraines, 
brain surgery ,or any  other neurol ogical condi tions that, in the opi[INVESTIGATOR_3078] n of the 
investi gator, increases the risk of parti cipat ing in the study .
[18]have known or ongoing psychiatric disorders considered clinically significant 
by [CONTACT_157669] y Rating Scale (C -SSRS) .
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 24
LY573144[19]currently use, or within the past [ADDRESS_182380] 6 months based on history  
at screening visit .
[20] s how evidence of human immunodeficiency  virus (HIV) infection and/or 
positive human HIV ant ibodies .
[
21] s how evidence of hepatit is C and/or positive hepat itis C ant ibody .
[
22] s how evidence of hepatit is B and/or positive hepat itis B surface antigen . 
[
23] are wom en with a posi tive pregnancy test or women who are l actating .
[24] intend to use over -the-counter or prescript ion medication, dietary  supplements 
within 14 days pri or to d osing and unt il study  discharge (apart from 
occasi onal acetaminophen or HRT) .
[25] h ave donated blood of more than 500 mL within 1 month prior to the 
screening visit. 
[
26] h ave an average weekly  alcoh ol intake that exceeds 21 units per week (males 
up to the age of 
65years ) and 14 units per week (females), or are unwilling to 
stop al coho l consumpt ion 48hours prior to dosing unt il the co mpletion of the 
study  (1 uni t = 12 oz or 360 m L of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 
mL o f distilled s pi[INVESTIGATOR_2120]).
[27] have a clinically  significant abnorm ality in the neurol ogical  examinat ion.
[
28] have current or a history  of orthostati c hypotensi on (>20 -mmHg drop in 
systolic blood pressure, o r >10 -mmHg drop in diastolic blood pressure) with 
or wi thout di zziness and/or syncope at screening or admissio n to the CRU 
upon repeat testing
.
[29] are unwilling to refrain fro m tobacco -or nicotine -containing products while in 
the CRU or are unable to ab ide by [CONTACT_157670].
[
30] have a n e stimated g lomerular filtration rate using Modificat ion of Diet in 
Renal Disease <60mL/min/1.73 m 2.
[31] have a history  of glauco ma.
[
32] have a history  of galactose intol erance, Lapp l actase deficiency ,or 
glucose -galactose m alabsorpti on.
[
33] in the opi[INVESTIGATOR_3078] n of the invest igator or sponsor, are unsuitable for inclusio n in the 
study .
6.2.1. Rationale for Exclusion of Certain Study Candidates
Criteria [1] through [7] define a healt hy population suitable for evaluat ion in a Phase 1 study.  
Criteria [8] and [9] prevent conflict of interest in study  parti cipants.  Criteria [10] through [33] 
predominant ly exclude medical condit ions, m edicati on into lerance, and concomitant medicat ion 
use that m ay confound the assessment of study  endpoints.
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 25
LY5731446.3. Lifestyle and/or Dietary Requirements
Throughout the study , subjects may undergo medical assessment sand review of compliance with 
requirements before continuing in the study .
6.3.1. Meals and Dietary Restrictions
On intensive PK sampling days (Days 1, 13, and 14), subjects will abstain fro m water 1 hour 
before and after dosing (except f or water given with the dose). Subjects will fast on these 
mornings for a minimum of [ADDRESS_182381] at 1 hour postdose at the discret ion of the 
investigator on all other day s.
6.3.2. C affeine, Alcohol, and Tobacco
Caffeine –Subjects will refrain fro m consuming xanthine -or caffeine -containing food and 
drinks fro m 48 hours prior to admissio n, and while resident at the CRU.
Alcohol –Subjects will not consume alcoho l for 48 hours prior to dosing , and while resident at 
the CRU.
Tobacco –Subjects will refrain fro m using tobacco-or nicotine -containing products while 
resident at the CRU.
6.3.3. Activity
No strenuous exercise will be allowed for 48 hours prior to a dmissio n unt il after the fo llow-up 
visit.
6.4. Screen Failures
Individuals who do not meet the criteria for participation in this study  (screen failure) may  notbe 
re-screened .
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page [ADDRESS_182382] ered
Table LAHT .2shows the treatment regimens for lasmiditan and topi[INVESTIGATOR_052].
Tablets of lasmiditan and topi[INVESTIGATOR_157647] h approximately 240mL o f 
room  temperature water in the morning of each dosing day in a sitt ing posit ion. Subjects will not 
be allowed to lie supi[INVESTIGATOR_2525] 2hours after dosing, unless clinically indicated or for study  
procedures.
Table LAHT.2. Treatment sAdministered
Treatment NameLasmiditan
LY573144Lasmiditan Placebo Topi[INVESTIGATOR_157648]-coated tablet Film-coated tablet Tablet
Unit Dose 
Strength(s)/Dosage 
Level(s)(1 200-mg) tablet/
200-mg lasmiditanNA (1 25-mg) tablet/
25-mg topi[INVESTIGATOR_052]
(2 25-mg) tablet/
50-mg topi[INVESTIGATOR_157649]:  NA = not applicable.
The dosing schedule is as fo llows:
Day 1: 1 oral  dose of l asmidi tan (1 × 200- mg tablet or placebo) in the morning
Two days fo llowing the init ial lasmiditan dose, s ubjects in the CRU will be administered the 
following topi [INVESTIGATOR_24175]:
Day 
3:starting dose of a single 25-mg tablet
Days 4 to 7: 2 oral doses of a single 25-mgtabletseparated by  [CONTACT_3450] 12 hours
Days 8to 13: 2 oral doses of50 m g (2 ×
25-mg tablets) each separated by  [CONTACT_3450] 
12 hours
Day 14: Final topi[INVESTIGATOR_157650] (2 × 25 -mg tablets) will be co -administered with 1 oral
dose of lasmiditan ( 1 × 200 -mgtablet or placebo) in the morning 
The invest igator or designee is responsible for
explaining the correct use of the IP(s) to the subject
verifying that instructions are fo llowed properly
maintaining accurate records of IPdispens ationand collect ion
and returning all unused medicat ionsto Lilly  or its desi gnee at the end of the stud y
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 27
LY573144Note : In some cases, the CRU may destroy  the materi al if, during the invest igativesite 
select ion, the evaluator has verified and documented that the site has appropriate facilit ies and 
written procedures to dispose of clinical materials .
7.1.1. Packaging and Labeling
Each tablet of lasmiditan contains [ADDRESS_182383] ive ingredient and is provided as bulk supplies in 
bottles.
The study  site will  obtain topi [INVESTIGATOR_052]. 
The IPwill be labeled according to the country’s regulatory  requi rements .
7.2. Method of Treatment Assi gnment
The sponsor (or designee) will be responsible for generat ing each of the rando mizat ion schedules 
and distribut ing them direct ly to the CRU pharmacist.
7.2.1. Selection and Timing of Doses
Doses of topi[INVESTIGATOR_157651] t imes on each dosing day 
(every  12 hours) except for Day  3and Day 14 when only 1 dose is administered .  On Day  14, 
topi[INVESTIGATOR_052] (50 mg) shoul d be co -administered with lasmiditan (200 m g)
.The actual time of all 
dose administrations will be recorded in the subject ’s electronic case report form ( eCRF ).
7.3. Blinding
Invest igator and subject blinding of lasmiditan will be m aintained throughout the conduct of the 
study  as described in the separate Blinding Plan. Topi [INVESTIGATOR_157652] -label.
Emergency codes will be available to the pharmacy .  A code, which reveals the lasmiditan 
treatm ent group for a specific study  subject, m ay be opened during the study  only  if the subject’s 
well-being requires knowledge of the subject’s treatment assignment.
If a subject’s study  treatm ent assignment is unblinded, the subject must be discont inued from the 
study , unless the invest igator obtains specific approval fro m a Lilly clinical pharmaco logist or 
clinical research physician (CRP) for the study  parti cipant to contin ue in the study .  During the 
study , emergency  unblinding shoul d occur only by [CONTACT_154519]’s em ergency 
code.
In case of an emergency , the invest igator has the sole responsibilit y for determining if unblinding 
of a subject’s treatm ent assi gnment is warranted for m edical management of the event.  The 
subject’s safet y must always be the first consideratio n in making such a determinat ion.  If the 
investigator decides that unblinding is warranted, it is the responsibilit y of the investi gator to 
promptly docum ent the decisio n and rationale and notify Lilly as soon as possible.
Upon com pletion of the study , all codes m ust be returned to Lilly  or its designee.
7.4. Dose Modification
Dose m odificat ion will not be allowed during the study . 
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 28
LY5731447.5. Preparation/Handl ing/Storage/Accountability
Only participants enro lled in the study  may receive IPor study materials, and only authorized 
CRU staff may  supply  or administer IP.All IPsshoul dbe stored in a nenvironmentally 
controlled and mo nitored (manual or automated) area in accordance with the labeled storage 
condi tions wi th access limited to the invest igator and authorized CRU staff.
The invest igator, institution, or the head of the medical inst itution (where applicable) is 
responsible for study  treatm ent accountabilit y, reconciliat ion, and record maintenance ( such as
recei pt, reconciliat ion,and final disposit ion records) .
7.6. Treatment Compliance
The IPwill be administered at the CRU , and documentati on of  treatm ent administrati on will 
occur at the CRU .
7.7. Concomitant Therapy
In general ,concomitant m edicat ion shoul d be avo ided;however ,acetaminophen (1 g, maximum  
4g/24 hours) may be administered at the discretion of the invest igator for treatment of headache ,
etc.  If the need for concomitant medicat ion (other than acetaminophen) arises, inclusi on or 
continuat ion of the subject may be at the discret ion of the invest igator after consultation wit h a 
Lilly clinical pharmaco logist orCRP .  Hormone repl acement the rapy is allowed per the inclusio n 
criteria. Any medicat ion used during the course of the study  must be documented.
7.8. Treatment after the End of the Study
Not applicable.
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page [ADDRESS_182384] meets 1 of the following condi tions after consultation with the Lilly -designated 
medical mo nitor:
alanine aminotransferase ( ALT) ,aspartate aminotransferase (AST ) >5X upper limit of 
norm al (ULN )
ALT or AST > 3X ULN sustained for more than 2 weeks or
ALT or AST >3X ULN and total bilirubin level (TBL) >2X ULN orinternat ional 
norm alized rati o>1.5 or
ALT or AST >3X ULN wit
h the appearance of fat igue, nausea, vo miting, right 
upper -quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%)
alkaline phosphatase (ALP ) >3X ULN
ALP >2.5X ULN and TBL >2X ULN
ALP >2.[ADDRESS_182385] with the appearance of fatigue, nausea, vo miting, right quadrant pain or 
tenderness, fever, rash, and/or eosinophilia (>5%) .
8.1.1. Discontinuation of Inadvertently Enrolled Subjects
If the sponsor or invest igator ident ifies a pati ent who di d not m eet enrollment cri teria and was 
inadvertent ly enro lled, a discussio n must occur between the Lilly  clinical pharmacol ogist/CRP
and the invest igator to determine if the patient may continue in the study.  If both agree it i s 
medically appropriate to continue, the invest igator must obtain documented approval fro m the 
Lilly clinical pharmaco logist/CRP to allow the inadvertent ly enro lled patient to con tinue in the 
study  with or wi thout continued treatment with IP.
8.2. Discontinuati onfrom the Study
Subjects will be discont inued under the following ci rcumstances:
Enrollment in any other clinical study  involving an IPor enrollment in any other ty pe of 
medical research judged not to be scient ifically or medically co mpat ible with this study
Parti cipation in the study  needs to be stopped for medical, safet y, regul atory , or other 
reasons consistent with applicable laws, r egulations, and good clinical pract ice (GCP)
Invest igator Decisio n
othe invest igator decides that the subject shoul d be discontinued from the study
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page [ADDRESS_182386] ive for treatment of the study  indicat ion, 
discontinuat ion from the study  occurs pri or to introducti on of  the new agent
Subject Decisio n
othe subject ,or legal representative ,requests to be withdrawn from the study .
8.3. Subjects Lost to Follow -up
Asubject will be considered lost to follow -up if he or she repeatedly  fails to return for scheduled 
visits and is unable to be con tacted by  [CONTACT_47365] .  Site personnel  are expected to m ake diligent 
attem pts to contact [CONTACT_105416] a scheduled visit or were otherwise unable to 
be followed up by [CONTACT_779].
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page [ADDRESS_182387] ivities, detailing the study  procedures and their timing 
(including tolerance limit s for timing).
Appendix [ADDRESS_182388] igator.
After the informed consent form ( ICF)is signed, CRU personnel will record, via eCRF ,the 
occurrence and nature of each subject ’s preexist ing conditions, including clinically significant 
signs and symptoms of the disease under treatment in the study .  Addit ionally , site personnel will  
record any change in the condit ion(s) and the occurrence and nature of any  AEs.
The invest igator will interpret and document whether or not anAE has a reasonab lepossib ility 
of being related to study treatment , or a study procedure, taking into account the di sease, 
concomitant treatment ,or pathol ogies.  
A “reasonable possibilit y”means that there is a potenti al cause and effect relat ionship between 
the IPand/or study procedure and the AE.
Planned surgeries should not be reported as AEs unless the underlying medical condit ion has 
worsened during the course of the study .
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page [ADDRESS_182389] ’s IP i s discont inued as a result of an AE, CRU personnel must report this to Lilly or 
its designee via eCRF .
9.2.1. Serious Adverse Events
An SAE is any  AE from this study  that resul ts in 1 of the f ollowing:
death
initial or prolonged inpatient hospi[INVESTIGATOR_3094]
a life- threatening experience ( i.e., immediate risk of dying)
persistent or significant disabilit y/incapacit y
congenital ano maly/birth defect
important medical events that may not be immediately life -threatening or result in death 
or hospi[INVESTIGATOR_313] m ay jeopardi zethe pati ent or may  requi re intervent ion to prevent [ADDRESS_182390] al ert the Lilly  CRP/ clinical pharmaco logist, or its desi gnee, of  any 
SAE as soon as pract ically possible.
Addit ionally , study site personnel  must al ert Lilly Global Patient Safet y,or its desi gnee ,of any 
SAE wi thin [ADDRESS_182391] 
discontinued from and/or com pleted the study  (the subject summary eCRF has been co mpleted).  
However, if the invest igator learns of any SAE, including a death, at any time after a subject has 
been discharged from the study , and he/she considers the event reasonably  possibly  related to the 
study treatm ent or study  parti cipat ion, the invest igator m ust prom ptly notify Lilly .
Pregnancy (maternal or paternal exposure to IP) does not meet the definit ion of an AE.  
However, to fulfill regulatory  requi rements any  pregnancy  should be reported followi ng the SAE 
process to collect data on the outcome for both mother and fetus.
[IP_ADDRESS]. Suspected Unexpected Serious Adverse Reactions 
Suspected unexpected serious adverse react ions (S[LOCATION_003]Rs) are serious events that are not listed 
in the IB and that the investigator reports as related to IPor procedure.  Lilly  has procedures that 
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page [ADDRESS_182392] label for advice on overdose.
Refer to the 2017 US Prescribing Information (Topi [INVESTIGATOR_157631] 
[https://www.topamax.co m/files/t opam ax.pdf]) . 
9.4. Safety
9.4.1. Laboratory Tests
For each subject , laboratory  testsdetailed in Appendix 2 shoul d be conducted accordi ng to the 
Schedule of Activities (Secti on2).
9.4.2. Vital Si gns
For each subject , vital sign measurem ents shoul d be conducted according to the Schedule of 
Activities (Secti on
 2).
Blood pressure and pulse rate should be measured after at l east [ADDRESS_182393] the same cuff size should 
be used throughout the study  for measurements of blood pressure.
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page [ADDRESS_182394] , ECGs should be collected according to the Schedule of Activit ies (Secti on 2) .
Any clinically  significant findings fro m ECGs that resul t in a di agnosis and that occur after the 
subject receives the first dose of the IP,shoul d be reported to Lilly ,or its desi gnee ,as an AE via 
eCRF . 
For each subject , a single 12-lead digital ECG will be collected according to the Schedule of 
Activities.  
Electrocardi ogram s must be recorded before collecting any  blood s amples.  Subjects
must be supi[INVESTIGATOR_17044] [ADDRESS_182395] igational site.
Electrocardiograms will be interpreted by  a qualified physician ( the investigator or qualified 
design ee) at the si te as soon after the time of ECG collect ion as possible, and ideally while the 
subject is still present, to determine whether the subject meets entry criteria at the relevant 
visit(s) and for immediate subject management, should any clinically relevant findings be 
ident ified.  
If a clinically significant finding is ident ified (including, but not limited to ,changes in QT/QTc 
interval  from baseline) after enrollment, the investigator will determine if the subject can 
continue in the study .  The invest igator ,or qualified designee ,is responsible for determining if 
any change in subject management i s needed ,and must document his/her review of the ECG 
printed at the time of collection.  Any new clinically relevant finding should be reported as an
AE.
9.4.4. C olumbia Suicide Severity Rating Scale
The C -SSRS (Posner 2007; Posner et al. 2007a,b) captures the occurrence, severit y, and 
frequency  of suicide -related thoughts and behaviors during the assessment period. The C -SSRS 
and a corresponding Self -Harm  Supplement Form  will be administered according to the 
Schedule of Activities by [CONTACT_157671]. Any significant change would 
need to be referred to a psy chiatri st.
If the invest igator determines that sui cide-related behaviors have occurred, the Lilly self -harm
follow-up form  will be used to collect additional informat ion to allow for a more complete
assessment of these behaviors. As noted above, subjects with any clinically significant change,
as determi ned by  [CONTACT_3170], will be referred to a psy chiatrist.
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page [ADDRESS_182396] ivities. 
The neuro logical examinat ion will include observation for tremors and testing of ocular 
movements, finger -to-nose and heel -to-shin testing, rapid alternat ing movements, tandem 
walking, strength testing ,and muscle stretch (deep) reflexes.  An experienced clinician will 
conduct the neurological examinat ion.  Pl ease see Appendix 6 for a descript ion of the techniques 
used.
Positive significant findings (such as nystagmus, dystaxia, ataxia, irregular alternating 
movements, and hyperr eflexia) on neuro logical examinat ion of ocul omotor testing, tandem 
walking, heel -to-shin, rapid alternat ing movements, finger -nose coordinat ion, and muscle stretch 
(deep) reflexes will be recorded as preexisting condit ions or AEs.  A clinically significant change 
from baseline or clinically significant new findings should be a considerat ion for discont inuat ion 
of study  drug.
9.4.6. Safety Monitoring
The Lilly clinical pharmaco logist or CRP /scientist will mo nitor safety  data throughout the course 
of the study .
Lilly will review SAEs wit hin time frames mandated by [CONTACT_17069].  The Lilly clinical 
pharmaco logist or CRP will periodically  review the following data:
trends in safety  data
laboratory  analy tes 
AEs 
When appropriate, the Lilly clinical pharmaco logist or CRP will consult wit h the funct ionally 
independent Global Pat ient Safety  therapeut ic area physician or clinical research scient ist.
[IP_ADDRESS]. Hepatic Safety
If a study  subject experiences elevated ALT ≥3X ULN, ALP ≥2X ULN, or el evated TBL ≥2X 
ULN, liver tests 
(Appendix 4 ) shoul d be repeated wi thin [ADDRESS_182397] or CRP .  Monitoring should continue unt il 
levels norm alize and/or are return ingto approximate baseline levels. 
Addit ional safet y data should be co llected if 1or more of  the f ollowing condit ions occur: 
elevation of serum  ALT to ≥5X ULN on 2or more consecutive blood tests
elevation ofserum  TBL to ≥2X ULN (except for cases of known Gilbert’s 
syndro me)
elevation of serum  ALP to ≥2X ULN on 2or more consecutive blood tests 
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 36
LY573144patient/subject di scontinued from treatment due to a hepat ic event or abnormalit y 
of liver tests
hepatic event considered to be a SAE.
9.5. Pharmacokinetic s
At the visit s and t imes specified in the Schedule of Act ivities, venous blood samples o f 
approximately  3mL each will be co llected to determine the plasma concentrations of lasmidi tan
and its metabolites .  Similarly, at times s pecified in the Schedule of Act ivities, 2mL of venous 
blood sam ples will  be collected to determine the plasma concentrations of topi[INVESTIGATOR_052]. A 
maximum o f 3samples may be collected at addit ional time po ints during the study  if warranted 
and agreed upon between both the invest igator and sponsor.  Instructions for the collect ion and 
handling of blood samples will be provided by  [CONTACT_456] .  The actual date and time (24-hour 
clock time) of each sampling will be recorded.
9.5.1. Bioanalysis
Samples will  be analyzed at a l aboratory  approved by  [CONTACT_17077] a facilit y 
designated by  [CONTACT_456].
Concentrations of lasmidi tan and its metabo lites will be assayed using a validated liquid 
chromatography  tandem -mass spectrometry  (LC-MS/MS )method.  Analyses of samples 
collected from subjects who received placebo are not planned.
Concentrations of topi[INVESTIGATOR_157653] a validated LC-MS/MS method.  
Bioanaly tical samples collected to m easure IP concentrations will be retained for a maximum o f 
[ADDRESS_182398] visit, or for a shorter 
period if local regulat ionsand/or ERBs impose shorter time limits , for the study  at a f acilit y 
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page [ADDRESS_182399] ion. 
9.8. Biomarker s
Not a pplicable.
9.9. Health Economics
Thissection is not applicable for this study.
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 38
LY57314410. Statistical Considerat ions and Data Analysis
10.1. Sample Size Determination
Approximately  30subjects will be enro lled, so that at least21subjects complete the study.   
Subjects will be rando mized in a 2:1 ratio of lasmidi tan 200 m g:placebo.   The sample size is 
custom ary for Phase [ADDRESS_182400] disposit ion will be provided at the end of the study . 
10.2.2. Study Participant Characteristics
The subjects’ age, sex, weight, height, BMI, race, and other demographic chara cterist ics will be 
recorded and summarized .
10.3. Statistical Anal yses
Statistical analysis o f this study  will be the responsibilit y of Eli Lilly and Com pany  or its 
designee .
Pharmacokinet icanalyses will be conducted on data fro m all subjects who receiv eat least [ADDRESS_182401] hoc analyses and inco mplete di sclosures of ana lyses.  
10.3.1. Safety Analyses
[IP_ADDRESS]. Clinical Evaluation of Safety
All IPand protocol  procedure AEs will be listed, and if the frequency o f events allows, safet y 
data will be summarized using descript ive methodol ogy.
The incidence of symptoms for each treatment will be presented by  [CONTACT_157672].  Symptoms reported to occur prior to enrollment will be 
distinguished from those reported as new or increased in severit y during the study .  Each 
symptom  will be classifi ed by  [CONTACT_941] m ost sui table term fro m themedical regulatory  dictionary.
The number of IP-related SAEs will be reported.
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page [ADDRESS_182402] ics.  Addi tional analysis will be performed if warranted upon review 
of the data.
10.3.2. Pharmacokinetic Analyses
[IP_ADDRESS]. Pharmacokinetic Parameter Estimation
Pharmac okinet ic parameter estimates for lasmiditan and its metabolites,and topi [INVESTIGATOR_157654] .
The primary  parameters for analysis will be C max, tmax,AUC( 0-tlast) and AUC from zero to 
infinit yfor lasmiditan and its metabo liteson Days 1 and 14,and C max, tmax, and AUC during 1 
dosing interval for topi [INVESTIGATOR_157655] s 13and 14.  Other noncompartmental parameters, such as 
half-life, apparent clearance, and apparent volume of distribut ion may be reported.
[IP_ADDRESS]. Pharmacokinetic Statistical Inference
Pharmacokinet ic parameter swill be eval uated to determine the impact of top iramate 
co-administrati on on the PK of a single dose of lasmiditan and its metabo lites.  Log -transformed 
Cmaxand AUC parameters will be evaluated in a linear mixed -effects m odel with fixed effects for 
treatm ent (l asmidi tan co -administered with topir amate [Day  14; test treatm ent] versus lasmiditan 
alone [Day 1; ref erence treatm ent]) , and a random effect for subject .  The treatment differences 
will be back -transformed to present the ratios of geometric means and the corresponding 90% 
confidence interval ( CI)
.
A similar analysis will be performed to determine the impact of co -administration of a single 
dose of lasmiditan on the steady -state PK of topi[INVESTIGATOR_052].  The model will include the fo llowing 
treatm ents:  topi [INVESTIGATOR_157622] -administered with lasmiditan (Day 14; test treatme nt) versus 
topi[INVESTIGATOR_157656] (Day 13; reference treatment).
The t maxwill be analyzed using the Wilco xon signed rank test.  Estimates of th e median 
difference based on th e observed medians, 90% CIs,and p -values fro m the Wilcoxon test will be 
calculated.
Addit ional analyses m ay be performed, as warranted.
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 40
LY57314411. References
Bialer M, Shekh -Ahmad T, Braun T, Halorsen M. Comparat ive steady -state pharmacokinet ic 
evaluat ion of immediate -release topi[INVESTIGATOR_157657]255, a once -daily  extended- release 
topi[INVESTIGATOR_157658]. Epi[INVESTIGATOR_8330] . 2013;54(8):[ADDRESS_182403] ions 
between topi[INVESTIGATOR_157659], hydrochlorothiazide, or propranolo l. Clin Pharmacol Drug 
Dev. 2014 a;3(5):[ADDRESS_182404] ions 
between topi[INVESTIGATOR_157660]. Epi[INVESTIGATOR_5612] . 2014 b;108(9):1519 -
1532.
Posner K
.State of the science: measurement of suicidal adverse events and the Co lumbia suicide 
severi ty rating scale. Boca Raton, FL: NCDEU; 2007.
Posner K, Melvin GA, Stanley B, Oquendo MA, Gould M. Factors in the assessment of 
suicidality in youth. CNS Spectr . 2007a;12(2) :156-162.
Posner K, Oquendo MA, Gould M, Stanley B, Davie s M. Col umbia Classificat ion Algorithm o f 
Suicide Assessment (C -CASA): classificat ion of sui cidal events in the FDA’s pediatric 
suicidal risk analysis of ant idepressants. Am J Psychiatry . 2007b;165 (7):1035 -1043.
Topi[INVESTIGATOR_157661]. Topomax web site. May 2017. Available 
at: https://www.topamax.co m/files/topamax.pdf .Accessed June 15, 2017.
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 41
LY573144Appendix 1. Abbreviations and Definitions
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 42
LY573144Term Definition
AE adverse event:  Any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product that does not necessarily have a causal 
relatio nship with this treatment.  An AE can therefore be any unfavorable and unintended 
sign (including an abnormal laboratory finding), symptom, or disease temporally a ssociated 
with the use of a medicinal (investigational) product, whether or not related to the medicinal 
(investigational) product.
ALP alkaline phosphatase
ALT alanine aminotransferase
AST aspartate aminotransferase
AUC area under the concentration versus time curve
BMI body mass index
CI confidence interval
Cmax maximum observed drug concentration
CNS central nervous system
complaint A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality , purity , durability , reliability , safety  or effectiveness, or 
performance of a drug or drug delivery system.
compliance Adherence to all the study -related requirements, good clinical practice (GCP) requirements, 
and the applicable regulatory requ irements.
confirmation A process used to confirm that laboratory test results meet the quality requirements defined 
by [CONTACT_57994].  
Confirmation will either occur immediately after initial testing or will require that samples 
be held to be re -tested at some defined time point, depending on the steps required to obtain 
confirmed results.
CRP clinical research physician:  Individual responsible for the medical conduct of the stu dy.  
Responsibilities of the CRP may be performed by a physician, clinical research scientist, 
global safety physician ,or other medical officer.
CRU clinical research unit
C-SS RS Columbia Suicide Severity Rating Scale
CYP cytochrome P450
ECG electrocardiogram
eCRF electronic case report form
enroll The act of assigning a subject to a treatment.  Subjects who are enrolled in the study are 
those who have been assigned to a treatment.
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page [ADDRESS_182405]
GCP good clinical practice
HIV human immunodeficiency virus
HRT hormone replacement therapy
IB Investigator’s Brochure
ICF informed consent form
ICH International Council for Harmonisation
informed consent A process by [CONTACT_9444] a subject voluntarily confirms his or her willingness to participate in a 
particular study , after having been informed of all aspects of the study that are relevant to 
the subject’s decision to participate. Informed consent is documented by [CONTACT_3553] a 
written, signed, and dated informed consent form .  
investigational 
product (IP)Apharmaceutical form of an active ingredient or placebo being test ed or used as a reference 
in a clinical study, including products already on the market when used or assembled 
(formulated or packaged) in a way different from the authorized form, or marketed products 
used for an unauthorized indication, or marketed products used to gain further information 
about the authorized form.
investigator A person responsible for the conduct of the clinical study at a study site.  If a study is 
conducted by a team of individuals at a study site, the investigator is the responsible leader 
of the team and may be called the principal investigator.
LC-MS/MS liquid chromatography tandem -mass spectrometry
legal 
representativeAn individual or judicial or other body authorized under applicable law to consent, on 
behalf of a prospective subject , to the subject’s participation in the clinical study.
non-
investigational 
product (non -IP)A product that is not being tested or used as a reference in the clinical study, but is provided 
to subjects and used in accordance with the protocol, such as concomitant or rescue/escape 
medication for preventative, diagnostic, or therapeutic reasons, medication to ensure 
adequate medical care, and/or products used to induce a physiological response.
open -label A study  in which there are no restrictions on knowledge of treatment allocation, therefore 
the investigator and the study participant are aware of the drug therapy received during the 
study.
PK pharmacokinetic(s)
QTc corrected QT interval
randomize The process of assigning subjects/ patients to an experimental group on a random basis .
SAE serious adverse event
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page [ADDRESS_182406] of determining if an individual meets minimum requirements to become part of a 
pool of potential candidates for participation in a clinical study .  
S[LOCATION_003]R suspected unexpected serious adverse reaction
TBL total bilirubin level
TEAE treatment -emergent adverse event:  Any untoward medical occurrence that emerges during 
a defined treatment period, having been absent pretreatment, or worsens relative to the 
pretreatment state, and does not necessarily have to have a causal relationship w ith this 
treatment 
tmax time of maximum observed drug concentration
ULN upper limit of normal
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 45
LY573144Appendix 2. Clinical Laboratory  Tests
Safety Laboratory Tests
Hematology Clinical Chemistry
Hematocrit Sodium
Hemoglobin Potassium
Erythrocy te count (RBC) Total CO 2
Mean cell volume Chloride
Mean cell hemoglobin Calcium
Mean cell hemoglobin concentration Phospho rus
Leukocytes (WBC) Gluco se (random)
Platelets Blood urea nitrogen (BUN)
Differential WBC absolute counts and % of Total protein
Neutrophils Albumin
Lymphocy tes Reflex total bilirubin
Monocytes Alkaline phosphatase (ALP)
Eosinophils Aspartate aminotransferase (AST)
Basophils Alanine aminotransferase (ALT)
Creatinine
Gamma -glutamyl transferase (GGT)
Urinalysis
Specific gravity
pH
Protein
Glucose Ethanol testing b
Ketones Urine drug screen b
Urine pregnancy test
Bilirubin Hepatitis B surface antigen a
Urobilinogen Hepatitis C antibody a
Blood HIV a
Nitrite Serum pregnancy test (females only) a
Urine microscopic (if positive result for blood) FSH (females only, if applicable) c
Abbreviations:  FSH = follicle -stimulating hormone; HIV = human immunodeficiency virus ;RBC = red blood cell; 
WBC = white blood cell.
aPerformed at screening only .
bUrine drug screen and ethanol level willbe performed locally at screening and may be repeated prior to 
admission to the clinical research unit and at other times indicated in the Schedule of Activities (Section 2).  
cPerformed at screening only, for confirmation of postmenopausal status.
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page [ADDRESS_182407] igator is responsible for
ensuring that the subject understands the nature of the study ,the potential risks and 
benefits of part icipating in the study , and that thei r parti cipat ion is vo luntary.
ensuring that informed consent is given by [CONTACT_72140].  Thi s
includes obtaining the appropriate signatures and dates on the ICF prior to the 
perform ance of any protocol  procedures and prior to the administration of IP.
answering any quest ions the subject may  have throughout the study  and sharing in a 
timely  manner any new inform ation that m ay be relevant to the subject’ swillingness to 
continue his or her participat ion in the study .
provi ding a copy  of the ICF to the parti cipant or the participant’s legal representative and 
retaining a copy  on file .
Ethical Review
The invest igator or appropriate local representative must give assurance that the ERB was 
properly const ituted and convened as required by  [CONTACT_72141] (ICH)
guidelines and other applicable laws and regulations.
Docum entati on of  ERB approval o f the protocol and the ICF must be provided to Lilly  before the 
study  may begin at the investi gative si te(s).  Lilly  or its representatives must approve the ICF 
before i t is used at the invest igative site(s).  All ICFs must be compliant with the ICH guideline 
on GCP.
The study  site’s ERB(s) shoul d be provided wi th the f ollowing:
the current IB and updates during the course of the study
ICF
relevant curri cula vi tae
Regulatory Considerations
This study  will be conducted in accordance wit hthe protocol  and wi th
1)consensus ethics principles derived fro m internat ional ethics guidelines, 
including the Declarat ion of Helsinki and Council for International 
Organizat ions of Medical Sciences Internat ional Ethical Guidelines 
2)applicable ICH GCP Guidelines
3)applicable laws and regulations
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page [ADDRESS_182408]-party  organi zation.
Protocol Signatures
The sponsor’s responsible medical o fficer will approve the protocol, confirming that, to the best 
of his or her knowledge, the protocol accurately describes the planned design and conduct of the 
study .
Final Report Signature
[CONTACT_47559], indicat ing 
agreem ent wi th the analyses, results, and conclusio ns of the report.
The sponsor’s responsible medical o fficer and statistician will sign/approve the final clinical 
study  report for this study , confirming that, to the best of his or her knowledge, the report 
accurately describes the conduct and results of the study .
Data Quality Assurance
To ensure accurate, complete, and reliable data, Lilly or its representatives will do the fo llowing:
provi de instructi onal materi al to the CRU , as appropri ate.
provi detraining to i nstruct the invest igators and study  coordinators.  This training will 
give instruction on the protocol, the complet ion of the eCRF s, and study  procedures.
make periodic visit s to the study  site.
be available for consultation and stay  in conta ct with the study  site personnel by  [CONTACT_2319], 
telephone, and/or fax.
review and evaluate eCRF data and/or use standard computer edits to detect errors in data 
collect ion.
conduct a qualit y review of the database .
In addit ion, Lilly or its representatives willperiodically check a sample of the subject data 
recorded against source documents at the study  site.  The study  may be audi ted by  [CONTACT_47557]/or 
regul atory  agencies at any  time.  Invest igators will be given notice before an audit occurs.
The invest igator wil l keep records of all original source data.  This might include laboratory  
tests, m edical records, and clinical notes.  If requested, the invest igator will provide the sponsor, 
applicable regulatory  agencies, and applicable ERBs with direct access to the o riginal  source 
docum ents.
Data Collection Tools/Source Data
An electronic data capture sy stem  will be used in this study .  The site must define and retain all 
source records and must maintain a record of any data where source data are directly entered into
the data capture system.
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page [ADDRESS_182409]/patient personal information co llected will be provided in a 
written docum ent to the subject/patient by  [CONTACT_456] .
Study and Site Closure
Discontinuation of Study Sites
Study  site parti cipat ion may be discont inued if Lilly  or its designee , the invest igator, or the ERB 
of the study  sitejudges it necessary for medical , safet y, regulatory , or other reasons consistent 
with applicable l aws, regul ations, and GCP.
Discontinuation of the Study
The study  will be di scontinued if Lilly or its designee judges it necessary  for m edical, safet y, 
regul atory , or other reasons consistent with applicable laws, regulat ions, and GCP.
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page [ADDRESS_182410] Alkaline Phosphatase Isoenzymes a
GGT
CPKAnti -smooth Muscle Antibody (or Anti-actin 
Antibody) a
Abbreviations:  ALT = alanine aminotransferase; AST = asp artate aminotransferase; CPK = creatinine 
phosphokinase; GGT = gamma -glutamyl transferase; Ig = immunoglobulin; INR = international normalized
ratio; RBC = red blood cell; WBC = white blood cell.
aAssay ed by [CONTACT_11007] -designated or local laboratory.
bReflex/confirmation dependent on regulatory requirements and/or testing availability .
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 50
LY573144Appendix 5. Blood Sampling Summary
This table summarizes the approximate number of venipunctures and blood volumes for all 
blood sampling ( screening, safet y laboratori es, and bioanaly tical assays) during the study .
Protocol H8H -MC -LAHT Sampling Summary
PurposeBlood Volume per Sample 
(mL)Number of Blood 
SamplesTotal Volume (m L)
Screening tests a [ADDRESS_182411] 10 mL 240
aAdditional samples may be drawn if needed for safety purposes.
bIncludes a potential 3 additional samples.
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page [ADDRESS_182412]
Arm dy staxia Finger -to-nose
Leg dy staxia Heel-to-shin
Scapular winging Strength testing
Hyperreflexia Muscle stretch (deep) reflexes
Dystaxia = incoordination of intentional movements
Neurological Examination
1) Test station (stance) and gait:
Inspect the patient for swaying when standing and for dy staxia o f gait.
Ask the pati ent to stand with feet together.
Ask the pati ent to take 6 steps along a straight line, walking heel to toe (tandem 
walking).
2) Test ey e movements:
Observe spontaneous ey e movements.
Observe the patient’s eyes as they pursue the examiner’s finger as it moves fro m 
side-to-side and up and down through the full range of ocular movements.
3) Test rapid alternat ing movements:
Thigh-slappi[INVESTIGATOR_157662].  Test each hand separately.
Dem onstrate the acti on to the patient by  [CONTACT_157673][INVESTIGATOR_007] y our own thi gh, 
alternat ing first wi th the palm and then wit h the back of the hand as rapi[INVESTIGATOR_157663], making an audible sound with each slap.
Instruct the patient to make act ions that sound exactly like yours.
4) Test arm movement:
Finger -to-nose test.  Ask the patient to extend his arms out in front.
Instruct him to place his index finger on the tip of his nose by  [CONTACT_157674] , and pl acing the ti p of his finger exact ly on the ti p of his nose, trying not 
to miss.
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 52
LY573144Inspect for intention tremor of the movement i n progress, and the precisio n with 
which the patient touches the tip of his nose.
If uncertain of the result, have the patient alternat ively touch his nose, y our finger, 
and his nose several times.
5) Test leg movement:
Heel-to-shin test.  The patient is s itting or supi[INVESTIGATOR_050].
Instruct the patient to place one heel precisely  on the opposi te knee and run the 
heel in a straight line precisely down the shin.
6) Strength testing:
Shoul der gi rdle.  Try  to press the pati ent’s arms down after he or she abducts
them toshoulder height.  Look for scapular winging.
Upper extremit ies.  Test the biceps, triceps, wrist dorsiflexors, and grip.  Test 
strength of finger abduct ion and extension.
Lower extremit ies.  Test hip flexors, abductors and adductors, knee flexors, foot 
dorsiflexors, invertors, and evertors.  Have patient do a deep knee bend to test 
knee extension.
Grade strength on a 0 to 5 scale.
7) Muscle stretch (deep) reflexes:
Biceps
Triceps
Quadri ceps (knee reflex)
Triceps surae (ankle jerk)
Grade 0 to 4+
Positive significant findings (such as nystagmus, dystaxia, ataxia, and irregular alternat ing 
movements*) on neurological examinat ion of oculomotor testing, tandem walking, heel -to-shin, 
rapid alternat ing movements, finger -nose coordination and muscle stretch (deep) reflexes will be 
recorded as pre -existing condit ions or adverse events.  Increase in severit y from baseline or new 
findings should be a considerat ion for discontinuatio n of study  drug.
* Enter “clumsiness” for irregular alternat ing movements on the eCRF as the pre -exist ing 
condi tion or adverse event.
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 53
LY573144Appendix 7. Protocol A mendment H8H-MC-LAHT(c) 
Summary  Safety , Tolerability , and Pharmacokinetics of 
Lasmiditan when Co -administered with Topi[INVESTIGATOR_157664]  H8H -MC-LAHT, Safet y, Tolerabilit y, and Pharmacokinet ics of Lasmiditan when Co -
administered with Topi[INVESTIGATOR_157614] ,has been amended.  The new protocol is 
indicated by  [CONTACT_11827] ( c) and will be used to conduct the study in place of any preceding 
versio n ofthe protocol .
Following feedback from the FDA from the Type C m eeting on 12 October 2017, the protocol 
was amended to include an assessment on l asmidi tan metabo lites.
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 54
LY573144Revised Protocol Sections
Note: All deletions have been ident ified by [CONTACT_58001] .
All additions have been ident ified by [CONTACT_58002] .
1. Protocol Synopsis
Statistical Analysis:
Safety parameters that will be assessed include safety laborator y parameters, vital signs, neurological examination, 
Columbia Suicide Severity Rating Scale , and 12-lead electrocardiogram parameters.  The parameters will be listed, 
and summarized using standard descriptive statistics , as appropriate .  
Pharmacokinetic parameter estimates for lasmiditan , its metabolites ,and topi[INVESTIGATOR_157665].   The parameters will be listed, and summarized using standard 
descriptive statistics , as appropriate .
Pharmacokinetic parameters will be evaluated to determine the impact of topi[INVESTIGATOR_157622] -administ ration on the PK of 
a single dose of lasmiditan and its metabolites .  Log -transformed C maxand area under the concentration versus time 
curve parameters will be evaluated in a linear mixed -effects model with fixed effects for treatment (lasmiditan co -
admin istered with topi[INVESTIGATOR_052] [Day 14; test treatment] versus lasmiditan alone [Day 1; reference treatment]), and a 
random effect for subject.  The treatment differences will be back -transformed to present the ratios of geometric 
means and the corresponding 90% confidence interval (CI).
A similar analysis will be performed to determine the impact of co -administratio n of a single dose of lasmiditan on 
the steady -state PK of topi[INVESTIGATOR_052].  The model will include the following treatments:  topi[INVESTIGATOR_157622] -administered 
with lasmiditan (Day 14; test treatment) versus topi[INVESTIGATOR_157623] (Day 13; reference treatment).
The t maxwill be analyzed using the Wilcoxon signed rank test.  Estimates of the median difference based on the 
observed medians, 90% CIs, and p -values from the Wilcoxon test will be calculated.
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 55
LY5731442. Schedule of A ctivit ies
Study Schedule Protocol H8H -MC-LAHT
Scree ning Study Days Discharg
eFollow -
up/EDComments
Procedure -28 to -2 
days 
prior to 
Day 1-1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Day 16 ~[ADDRESS_182413] dose
Lasmiditan and 
Metabolite PK 
SamplesPredose, 
0.5, 1, 
1.5, 2, 3, 
4, 6, 8, 
12h24, 
36
h48
hPredose, 
0.5, 1, 
1.5, 2, 
2.5, 3, 
4, 6, 8, 
12h24, 
36h48h
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 56
LY5731444. Objectives and Endpoints
Table LAHT. 1. Objectives and Endpoints
Objectives Endpoints
Primary
To evaluate the safety and tolerability of a single dose 
of lasmiditan in combination with topi[INVESTIGATOR_157618]. A summary of the number of treatment -emergent 
adverse events and serious adverse events
Secondary
To evaluate the pharmacokinetics of lasmiditan alone 
and in combination with topi[INVESTIGATOR_157617].
To evaluate the pharmacokinetics of topi[INVESTIGATOR_157620] .Cmax, tmax, AUC([ADDRESS_182414]) and AUC(0 -∞)
Cmax, tmax, and AUC 
Exploratory
To evaluate the pharmacokinetics of lasmiditan 
metabolites alone and in combination with topi[INVESTIGATOR_157636].Cmax, tmax, AUC([ADDRESS_182415]) ,and AUC(0 -∞)
Abbreviations:  AUC([ADDRESS_182416]) = area under the concentration versus time curve from time zero to time t, where t is 
the last time point with a measurable concentration; AUC(0 -∞)= area under the concentration versus time curve
from zero to infinity; AUC= area under the concentration versus time curve during 1 dosing interval; Cmax= 
maximum observed drug concentration ; tmax= time to Cmax.
5.1. Overall Design
This is a Phase [ADDRESS_182417] -blind administration of 
lasmiditan/placebo conducted in healthy subjects.
Subjects will be admitted to the CRU on Day  -1 and are expected to remain a resident until all 
assessments are completed on Day  16;however ,subjects m ay be allowed to leave the CRU at 
the discret ion of the invest igator. 
Study  governance considerations are described in detail in Appendix 3 .
Lasmiditan and topi[INVESTIGATOR_157637]. Subjects will be rando mly 
assigned in a 2:1 ratio to receive lasmiditan or placebo on both lasmiditan dosing days (Days 1 
and 14).  A single oral dose of study  drug (200 -mg lasmiditan or pla cebo) will be administered in 
the morning on Day 1.  After l asmidi tan wash -out, topi [INVESTIGATOR_157638] 100 mg on 
Days 3 to 13.  On Day  14, 1 oral dose of l asmidi tan 200 m gor placebo will be co -administered
with the final topi[INVESTIGATOR_157639] (50 mg) in the morning.
Blood sam pling for PK assessment will be conducted predose and at time points up to 48 hours 
postdose on Days 1 and 14 for the measurement of plasma concentrations of lasmiditan and i
ts 
metabo lites.  Blood sam ples will  also be collected pr edose and up to 12 hours postdose on Day s 
13 and 14 for the measurement of plasma concentrations o f topi[INVESTIGATOR_052].
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page [ADDRESS_182418] 10 days following co -administration of lasmiditan and 
topi[INVESTIGATOR_052] (Day  14).
9.5. Pharmacokinetics
At the visit s and t imes specified in the Schedule of Act ivities, venous blood samples o f 
approximately  3mL each will be co llected to determine the plasma concentrations of lasmiditan
and itsmetabolite s.  Similarly, at times specified in the Schedule of Act ivities, [ADDRESS_182419] ion and 
handling of blood samples will be provided by  [CONTACT_456] .  The actual date and time (24 -hour 
clock time) of each sampling will be recorded.
9.5.1. Bioanalysis
Samples will  be analyzed at a l aboratory  approved b y the sponsor and stored at a facilit y 
designated by  [CONTACT_456].
Concentrations of lasmiditan and its metabo liteswill be assayed using a validated liquid 
chromatography  tandem -mass spectrometry  (LC-MS/MS) method.  Analyses of samples 
collected from subje cts who received placebo are not planned. 
Concentrations of topi[INVESTIGATOR_157653] a validated LC -MS/MS m ethod.  
Bioanaly tical samples collected to m easure IP concentrations will be retained for a maximum o f 
[ADDRESS_182420] oratory  analyses.
[IP_ADDRESS]. Pharmacokinetic Parameter Estimation
Pharmacokinet ic parameter estimates for lasmiditan and i ts metabo lites,and topi [INVESTIGATOR_157666].
The primary  parameters for analysis will be C max, tmax, AUC([ADDRESS_182421]) and AUC from  zero to 
infinit y for lasmiditan and its metabo liteson Days 1 and 14, and C max, tmax, and AUC during 1 
dosing interval for topi[INVESTIGATOR_157655] s 13 and 14.  Other noncompartmental parameters, such as 
half-life, apparent clearance, and apparent volume of distribut ion may be reported.
[IP_ADDRESS]. Pharmacokinetic Statistical Inference
Pharmacokinet ic parameters will be evaluated to determine the impact of topi[INVESTIGATOR_157667]-administration on the PK of a single dose of lasmiditan and its metabo lites.  Log -transformed 
Cmaxand AUC parameters will be evaluated in a linear mixed -effects m odel with fixed effects for 
treatm ent (l asmidi tan co -administered with topi[INVESTIGATOR_052] [Day  14; test treatment] versus lasmiditan 
alone [Day 1; ref erence treatm ent]), and a random effect for subject.  The treatment differences 
will be back -transf ormed to present the ratios of geometric means and the corresponding 90% 
confidence interval (CI).
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 58
LY573144Appendix 5. Blood Sampling Summary
This table summarizes the approximate number of venipunctures and blood volumes for all 
blood sampling ( screening, safet y laboratori es, and bioanaly tical assays) during the study .
Protocol H8H -MC -LAHT Sampling Summary
PurposeBlood Volume per Sample 
(mL)Number of Blood 
SamplesTotal Volume (mL)
Screening tests a [ADDRESS_182422] 10 mL 240
aAdditional samples may be drawn if needed for safety purposes.
bIncludes a potential 3 additional samples.
Leo Document ID = 9147c1ba-6644-46bd-a6c6-a9340b641595
Approver: 
Approval Date & Time: 19-Oct-2017 17:11:26 GMT
Signature [CONTACT_32869]: Approved
Approver: 
Approval Date & Time: 20-Oct-2017 08:36:56 GMT
Signature [CONTACT_32869]: Approved
[COMPANY_003]
[COMPANY_003]